Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria

Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria

Background: Chronic spontaneous urticaria (CSU) is a common condition treated by allergist/immunologists, but the only FDA-approved biologic medication, omalizumab, may be underutilized globally. Objective: This study was performed to determine the global prescription of omalizumab for treatment of...

Full description

Bibliographic Details
Main Authors: Christine J. Rubeiz, MD, Ricardo Asero, MD, Stephen Betschel, HBSc, MD, FRCP (C), Timothy Craig, DO, Anete Grumach, MD, PhD, Michihiro Hide, MD, PhD, David Lang, MD, Michael Levin, MD, PhD, Hilary Longhurst, MA, PhD, FRACP, FRCPath, Eli Magan, MD, Marcus Maurer, MD, Romi Saini, MD, Gordon Sussman, MD, Elias Toubi, MD, Dinh Nguyen Van, MD, PhD, Torsten Zuberier, MD, Jonathan A. Bernstein, MD
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:World Allergy Organization Journal
Subjects:
Chronic spontaneous urticaria
Clinical research
Safety
Adverse effects
Monitoring
Biologics
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455123001187

Internet

http://www.sciencedirect.com/science/article/pii/S1939455123001187

Similar Items